SCHEMBL7017334

SCHEMBL7017334

CCOC(=O)COC1CCN(CC(=O)O)CC1

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 4/20 0.42
ITGA2B P08514 4/20 0.42
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTGIR P43119 4/20 0.37
PKM P14618 1/20 0.35
HSD17B10 Q99714 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15200304 0.84 HSD17B10 (0.41) KDM4EALDH1A1SMN1; SMN2PTGIRPKM
SCHEMBL30771999 0.82 ITGB3 (0.42) ITGB3ITGA2BKMT2ASMN1; SMN2
SCHEMBL28539475 0.81 ITGB3 (0.49) ITGB3ITGA2BKMT2AALDH1A1SMN1; SMN2
SCHEMBL8912151 0.81 ITGB3 (0.46) ITGB3ITGA2BKMT2AALDH1A1SMN1; SMN2
SCHEMBL25713253 0.78 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2PKMHSD17B10
SCHEMBL11395101 0.78 BCHE (0.55) ALDH1A1
SCHEMBL13858459 0.77 ITGB3 (0.43) ITGB3ITGA2BKMT2AALDH1A1PKM
SCHEMBL3248382 0.77 KMT2A (0.51) ITGB3ITGA2BKMT2AALDH1A1
SCHEMBL3248583 0.77 KMT2A (0.47) ITGB3ITGA2BKMT2AALDH1A1
SCHEMBL15997367 0.77 HSD17B10 (0.44) KDM4EALDH1A1PKMHSD17B10GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224186-B1 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION MILLENNIUM PHARM INC (US) 2003-09-24 EP disclosed
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation MILLENNIUM PHARMACEUTICALS, INC. 2003-03-20 US disclosed
EP-1224186-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2002-07-24 EP disclosed
WO-2001030780-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation PF4, PFKP, FGB ITGB3 139/4885ITGA2B 90/4885KMT2A 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.